Pharmaceutical Investing Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights
Pharmaceutical Investing Clementia Initiates Phase 2 MO-Ped Trial for Palovarotene in Patients with Multiple Osteochondromas
Bio-Path Announces Interim Data from Phase 2 Clinical Trial of Prexigebersen in Combination with Low Dose Cytarabine
Pharmaceutical Investing Insmed Submits New Drug Application to FDA for ALIS in NTM Lung Disease Caused by MAC
Pharmaceutical Investing Menlo Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
Pharmaceutical Investing Altimmune Announces Positive Data From Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine and Provides an Update
Pharmaceutical Investing Positive Phase 1/2 Results of AKCEA-APOCIII-LRx Presented at American College of Cardiology Annual Scientific Session & Expo
Pharmaceutical Investing Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV Vaccine
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor
